A bid from Lynparza (olaparib) co-developers AstraZeneca (LSE: AZN) and Merck & Co (NYSE: MRK) to broaden the label in the USA has been granted Priority Review status.
The firms want to market the product to treat certain people with metastatic castration-resistant prostate cancer (mCRPC). The indication relates to people with HRR gene mutations.
The US Food and Drug Administration (FDA) will reach a decision in the second quarter of 2020, drawing from results from the Phase III PROfound trial.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze